Citations (65)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Ines Chendo & Joaquim J Ferreira. (2016) Pimavanserin for the treatment of Parkinson’s disease psychosis. Expert Opinion on Pharmacotherapy 17:15, pages 2115-2124.
Read now
Read now
Ricardo P. Garay, Michel Bourin, Evelyne de Paillette, Ludovic Samalin, Ahcène Hameg & Pierre-Michel Llorca. (2016) Potential serotonergic agents for the treatment of schizophrenia. Expert Opinion on Investigational Drugs 25:2, pages 159-170.
Read now
Read now
Joseph H Friedman. (2013)
Pimavanserin for the treatment of Parkinson's disease psychosis. Expert Opinion on Pharmacotherapy 14:14, pages 1969-1975.
Read now
Read now
Bjørn H Ebdrup, Hans Rasmussen, Jørn Arnt & Birte Glenthøj. (2011) Serotonin 2A receptor antagonists for treatment of schizophrenia. Expert Opinion on Investigational Drugs 20:9, pages 1211-1223.
Read now
Read now
Kimberly E Vanover & Robert E Davis. (2010) Role of 5-HT2A receptor antagonists in the treatment of insomnia. Nature and Science of Sleep 2, pages 139-150.
Read now
Read now
Thomas Müller. (2010) New small molecules for the treatment of Parkinson's disease. Expert Opinion on Investigational Drugs 19:9, pages 1077-1086.
Read now
Read now
Shannon S Sullivan & Christian Guilleminault. (2009) Emerging drugs for insomnia: new frontiers for old and novel targets. Expert Opinion on Emerging Drugs 14:3, pages 411-422.
Read now
Read now
Articles from other publishers (58)
Ryan H. Gumpper & Bryan L. Roth. (2023) Psychedelics: preclinical insights provide directions for future research. Neuropsychopharmacology 49:1, pages 119-127.
Crossref
Crossref
Negar Sheikhi, Maryam Bahraminejad, Mina Saeedi & Seyedeh Sara Mirfazli. (2023) A review: FDA-approved fluorine-containing small molecules from 2015 to 2022. European Journal of Medicinal Chemistry 260, pages 115758.
Crossref
Crossref
Liqian Zhou, Yuzhuang Wang, Lihong Peng, Zejun Li & Xueming Luo. (2023) Identifying potential drug-target interactions based on ensemble deep learning. Frontiers in Aging Neuroscience 15.
Crossref
Crossref
Bryan L. RothRyan H. Gumpper. (2023) Psychedelics as Transformative Therapeutics. American Journal of Psychiatry 180:5, pages 340-347.
Crossref
Crossref
Jitendra Kumar Sinha, Punya Sachdeva, Faizan Ahmad, Jasmine Sarkar, Raafiah Izhar, Ayesha Rahman & Shampa Ghosh. 2023. Cognizance of Schizophrenia:: A Profound Insight into the Psyche. Cognizance of Schizophrenia:: A Profound Insight into the Psyche
149
179
.
Milagros Rojas, Mervin Chávez-Castillo, Pablo Duran, Ángel Ortega, María Judith Bautista-Sandoval, Juan Salazar, Manuel Riaño-Garzón, Maricarmen Chacín, Oscar Medina-Ortiz, Jim Palmar, Lorena Cudris-Torres & Valmore Bermúdez. (2022) Psychosis in Parkinson’s Disease: Looking Beyond Dopaminergic Treatments. Current Pharmaceutical Design 28:33, pages 2725-2741.
Crossref
Crossref
Alexander J. Poznanski & Esther Akinyemi. (2022) Recent Advances in Psychopharmacology. Advances in Psychiatry and Behavioral Health 2:1, pages 253-266.
Crossref
Crossref
Maria C. Lobo, Thomas S. Whitehurst, Stephen J. Kaar & Oliver D. Howes. (2022) New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics. Neuroscience & Biobehavioral Reviews 132, pages 324-361.
Crossref
Crossref
David M. Taylor, Thomas R. E. Barnes & Allan H. Young. 2021. The Maudsley Prescribing Guidelines in Psychiatry. The Maudsley Prescribing Guidelines in Psychiatry
1
224
.
Zhen-zhen Liu, Xiao-ning Liu, Rui-cheng Fan, Yu-ping Jia, Qing-ke Zhang, Xin-qing Gao, Yu-qing Wang, Meng-qing Yang, Li-zhen Ji, Yong-qing Zhou, Hong-li Li, Ping Li & Bo Tang. (2021) Identification of pimavanserin tartrate as a potent Ca2+-calcineurin-NFAT pathway inhibitor for glioblastoma therapy. Acta Pharmacologica Sinica 42:11, pages 1860-1874.
Crossref
Crossref
Mohammad Mojeeb Gulzar Khan, Pawar Vivek Laxman, Abdul Talib, Sandip Dinkar Firke, Mohan G Kalaskar & Atul Arun Shirkhedkar. (2021) Development and validation of pimavanserin tartrate by normal phase- HPTLC method. International Journal of Pharmaceutical Chemistry and Analysis 8:2, pages 75-78.
Crossref
Crossref
Jian Jin, Kunxiao Zhang, Fei Dou, Chao Hao, Yifang Zhang, Xudong Cao, Lanchang Gao, Jiaying Xiong, Xin Liu, Bi-Feng Liu, Guisen Zhang & Yin Chen. (2020) Isoquinolinone derivatives as potent CNS multi-receptor D2/5-HT1A/5-HT2A/5-HT6/5-HT7 agents: Synthesis and pharmacological evaluation. European Journal of Medicinal Chemistry 207, pages 112709.
Crossref
Crossref
Daniel Hoyer. (2020) Targeting the 5-HT system: Potential side effects. Neuropharmacology 179, pages 108233.
Crossref
Crossref
Ling Huang, Lanchang Gao, Xiaohua Zhang, Lei Yin, Jintao Hu, Ting Song & Yin Chen. (2020) Synthesis and pharmacological evaluation of piperidine (piperazine)-amide substituted derivatives as multi-target antipsychotics. Bioorganic & Medicinal Chemistry Letters 30:20, pages 127506.
Crossref
Crossref
Harika M. Reddy, Joshua S. Poole, Gerald A. Maguire & Stephen M. Stahl. (2020) New Medications for Neuropsychiatric Disorders. Psychiatric Clinics of North America 43:2, pages 399-413.
Crossref
Crossref
Geetha Bhavani Koduri, Hari Babu BollikollaRamachandran DittakaviSrinivasu Navuluri. (2018) Quantification of Pimavanserin in Bulk and Tablet Dosage Form Using A Stability Indicating High Performance Liquid Chromatographic Method. Pharmaceutical Sciences 24:4, pages 291-297.
Crossref
Crossref
Stefano Aringhieri, Marco Carli, Shivakumar Kolachalam, Valeria Verdesca, Enrico Cini, Mario Rossi, Peter J. McCormick, Giovanni U. Corsini, Roberto Maggio & Marco Scarselli. (2018) Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences. Pharmacology & Therapeutics 192, pages 20-41.
Crossref
Crossref
Wenying Wu, Yanjie Chu, Shixiao Wang, Xiaoyang Sun, Jingjing Zhang, Yannian Wang & Xiaohui Chen. (2018) Investigation of metabolic profile of pimavanserin in rats by ultrahigh-performance liquid chromatography combined with Fourier transform ion cyclotron resonance mass spectrometry. Rapid Communications in Mass Spectrometry 32:3, pages 269-276.
Crossref
Crossref
Matthias M. Herth & Gitte M. Knudsen. 2018. 5-HT2A Receptors in the Central Nervous System. 5-HT2A Receptors in the Central Nervous System
85
134
.
Shixiao Wang, Yang Wang, Shuang Gao, Yuanyuan Zhang, Hanpei Wang, Longshan Zhao, Kaishun Bi, Shaojie Wang & Xiaohui Chen. (2017) Development of a UPLC–MS/MS method for determination of pimavanserin tartrate in rat plasma: Application to a pharmacokinetic study. Journal of Pharmaceutical Analysis 7:6, pages 406-410.
Crossref
Crossref
Austen B. Casey & Clinton E. Canal. (2017) Classics in Chemical Neuroscience: Aripiprazole. ACS Chemical Neuroscience 8:6, pages 1135-1146.
Crossref
Crossref
Alice Ameline, Pascal Kintz, Caroline Blettner, Éric Bayle & Jean-Sébastien Raul. (2017) Identification of 25I-NBOMe in two intoxications cases with severe hallucinations. Toxicologie Analytique et Clinique 29:1, pages 117-122.
Crossref
Crossref
Raquel N. Taddei, Seyda Cankaya, Sandeep Dhaliwal & K. Ray Chaudhuri. (2017) Management of Psychosis in Parkinson’s Disease: Emphasizing Clinical Subtypes and Pathophysiological Mechanisms of the Condition. Parkinson's Disease 2017, pages 1-18.
Crossref
Crossref
Shengdi Chen, Piu Chan, Shenggang Sun, Haibo Chen, Baorong Zhang, Weidong Le, Chunfeng Liu, Guoguang Peng, Beisha Tang, Lijuan Wang, Yan Cheng, Ming Shao, Zhenguo Liu, Zhenfu Wang, Xiaochun Chen, Mingwei Wang, Xinhua Wan, Huifang Shang, Yiming Liu, Pingyi Xu, Jian Wang, Tao Feng, Xianwen Chen, Xingyue Hu, Anmu Xie & Qin Xiao. (2016) The recommendations of Chinese Parkinson’s disease and movement disorder society consensus on therapeutic management of Parkinson’s disease. Translational Neurodegeneration 5:1.
Crossref
Crossref
Cornelis J. Van der Schyf. (2016) Psychotropic Drug Development Strategies that Target Neuropsychiatric Etiologies in Alzheimer's and Parkinson's Diseases. Drug Development Research 77:8, pages 458-468.
Crossref
Crossref
Harini Sarva & Claire Henchcliffe. (2016) Evidence for the use of pimavanserin in the treatment of Parkinson’s disease psychosis. Therapeutic Advances in Neurological Disorders 9:6, pages 462-473.
Crossref
Crossref
Xudong Cao, Yin Chen, Yifang Zhang, Yinli Qiu, Minquan Yu, Xiangqing Xu, Xin Liu, Bi-Feng Liu & Guisen Zhang. (2016) Synthesis and biological evaluation of new 6-hydroxypyridazinone benzisoxazoles: Potential multi-receptor-targeting atypical antipsychotics. European Journal of Medicinal Chemistry 124, pages 713-728.
Crossref
Crossref
Oluwadamilola O. Ojo & Hubert H. Fernandez. (2016) Current Understanding of Psychosis in Parkinson’s Disease. Current Psychiatry Reports 18:10.
Crossref
Crossref
Robert H. Howland. (2016) Pimavanserin: An Inverse Agonist Antipsychotic Drug. Journal of Psychosocial Nursing and Mental Health Services 54:6, pages 21-24.
Crossref
Crossref
Anna Bielenica, Ewa Kędzierska, Michał Koliński, Sebastian Kmiecik, Andrzej Koliński, Ferdinando Fiorino, Beatrice Severino, Elisa Magli, Angela Corvino, Ilaria Rossi, Paola Massarelli, Anna E. Kozioł, Aleksandra Sawczenko & Marta Struga. (2016) 5-HT 2 receptor affinity, docking studies and pharmacological evaluation of a series of 1,3-disubstituted thiourea derivatives. European Journal of Medicinal Chemistry 116, pages 173-186.
Crossref
Crossref
Susana Aznar & Mona El-Sayed Hervig. (2016) The 5-HT2A serotonin receptor in executive function: Implications for neuropsychiatric and neurodegenerative diseases. Neuroscience & Biobehavioral Reviews 64, pages 63-82.
Crossref
Crossref
Walter Dunn & Stephen R. Marder. (2015) Novel Treatments of Psychosis. Current Behavioral Neuroscience Reports 2:2, pages 119-126.
Crossref
Crossref
Daniel Hoyer. 2015. Antitargets and Drug Safety. Antitargets and Drug Safety
57
80
.
Shashikanth Ponnala, Nirav Kapadia, Hernán A. Navarro & Wayne W. Harding. (2014)
Aporphinoid Antagonists of 5-HT
2A
Receptors: Further Evaluation of Ring A Substituents and the Size of Ring C
. Chemical Biology & Drug Design 84:5, pages 558-566.
Crossref
Crossref
Justin L. Poklis, Carol R. Nanco, Michelle M. Troendle, Carl E. Wolf & Alphonse Poklis. (2013) Determination of 4‐bromo‐2,5‐dimethoxy‐N‐[(2‐methoxyphenyl)methyl]‐benzeneethanamine (25B‐NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Testing and Analysis 6:7-8, pages 764-769.
Crossref
Crossref
Mona Boules, Paul Fredrickson, Amber Muehlmann & Elliott Richelson. (2014) Elucidating the Role of Neurotensin in the Pathophysiology and Management of Major Mental Disorders. Behavioral Sciences 4:2, pages 125-153.
Crossref
Crossref
J. L. Poklis, D. J. Clay & A. Poklis. (2014) High-Performance Liquid Chromatography with Tandem Mass Spectrometry for the Determination of Nine Hallucinogenic 25-NBOMe Designer Drugs in Urine Specimens. Journal of Analytical Toxicology 38:3, pages 113-121.
Crossref
Crossref
Justin L. Poklis, Kelly G. Devers, Elise F. Arbefeville, Julia M. Pearson, Eric Houston & Alphonse Poklis. (2014) Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Science International 234, pages e14-e20.
Crossref
Crossref
Clinton E. Canal, Tania Cordova-Sintjago, Yue Liu, Myong S. Kim, Drake Morgan & Raymond G. Booth. (2013) Molecular Pharmacology and Ligand Docking Studies Reveal a Single Amino Acid Difference between Mouse and Human Serotonin 5-HT2A Receptors That Impacts Behavioral Translation of Novel 4-Phenyl-2-dimethylaminotetralin Ligands. Journal of Pharmacology and Experimental Therapeutics 347:3, pages 705-716.
Crossref
Crossref
Oscar Bernal-Pacheco & Hubert H. Fernandez. 2013. Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Movement Disorders. Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Movement Disorders
153
162
.
. 2013. Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Movement Disorders. Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Movement Disorders
109
210
.
Clinton E. Canal, Raymond G. Booth & Drake Morgan. (2013) Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model. Neuropharmacology 70, pages 112-121.
Crossref
Crossref
S Miyamoto, N Miyake, L F Jarskog, W W Fleischhacker & J A Lieberman. (2012) Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Molecular Psychiatry 17:12, pages 1206-1227.
Crossref
Crossref
Matthias M. Herth, Vasko Kramer, Nic Gillings, Frank Rösch & Gitte M. Knudsen. (2012) Direct radiofluorination of [18F]MH.MZ for 5-HT2A receptor molecular imaging with PET. Journal of Labelled Compounds and Radiopharmaceuticals 55:9, pages 354-358.
Crossref
Crossref
Jelveh Lameh, Krista McFarland, Jorgen Ohlsson, Fredrik Ek, Fabrice Piu, Ethan S. Burstein, Ali Tabatabaei, Roger Olsson, Stefania Risso Bradley & Douglas W. Bonhaus. (2011) Discovery of potential antipsychotic agents possessing pro-cognitive properties. Naunyn-Schmiedeberg's Archives of Pharmacology 385:3, pages 313-323.
Crossref
Crossref
Bryan L. Roth. (2011) Irving Page Lecture: 5-HT2A serotonin receptor biology: Interacting proteins, kinases and paradoxical regulation. Neuropharmacology 61:3, pages 348-354.
Crossref
Crossref
Jaime M. Monti. (2011) Serotonin control of sleep-wake behavior. Sleep Medicine Reviews 15:4, pages 269-281.
Crossref
Crossref
Adrian Newman-Tancredi & Mark S. Kleven. (2011) Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology 216:4, pages 451-473.
Crossref
Crossref
Francisco López-Muñoz & Cecilio Álamo. (2011) Neurobiological Background for the Development of New Drugs in Schizophrenia. Clinical Neuropharmacology 34:3, pages 111-126.
Crossref
Crossref
Anders Ettrup, Martin Hansen, Martin A. Santini, James Paine, Nic Gillings, Mikael Palner, Szabolcs Lehel, Matthias M. Herth, Jacob Madsen, Jesper Kristensen, Mikael Begtrup & Gitte M. Knudsen. (2010) Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers. European Journal of Nuclear Medicine and Molecular Imaging 38:4, pages 681-693.
Crossref
Crossref
Jennifer G. Goldman. (2011) New Thoughts on Thought Disorders in Parkinson's Disease: Review of Current Research Strategies and Challenges. Parkinson's Disease 2011, pages 1-12.
Crossref
Crossref
Shannon S. Sullivan. (2010) Insomnia Pharmacology. Medical Clinics of North America 94:3, pages 563-580.
Crossref
Crossref
Michael J Sateia. 2010. Insomnia. Insomnia
427
435
.
Michael Poyurovsky. (2018) Acute antipsychotic-induced akathisia revisited. British Journal of Psychiatry 196:2, pages 89-91.
Crossref
Crossref
Vincent J. Aloyo, Kelly A. Berg, William P. Clarke, Umberto Spampinato & John A. Harvey. 2010. Membrane Proteins as Drug Targets. Membrane Proteins as Drug Targets
1
40
.
Spyridon Papapetropoulos & Blake K. Scanlon. 2010. Neuropsychiatric Disorders. Neuropsychiatric Disorders
51
64
.
Nico J. Diederich, Gilles Fénelon, Glenn Stebbins & Christopher G. Goetz. (2009) Hallucinations in Parkinson disease. Nature Reviews Neurology 5:6, pages 331-342.
Crossref
Crossref
Falko Biedermann & W Wolfgang Fleischhacker. (2009) Antipsychotics in the early stage of development. Current Opinion in Psychiatry 22:3, pages 326-330.
Crossref
Crossref